In a filing, Vera Therapeutics Inc revealed its Chief Legal Officer Carter Jason S unloaded Company’s shares for reported $0.11 million on Nov 21 ’25. In the deal valued at $27.82 per share,3,864 shares were sold. As a result of this transaction, Carter Jason S now holds 49,136 shares worth roughly $1.66 million.
Then, Carter Jason S bought 3,864 shares, generating $107,690 in total proceeds.
Before that, Young Joseph R sold 15,000 shares. Vera Therapeutics Inc shares valued at $435,874 were divested by the SVP, FINANCE, CHIEF ACCT OFFCR at a price of $29.06 per share. As a result of the transaction, Young Joseph R now holds 47,839 shares, worth roughly $1.61 million.
BofA Securities initiated its Vera Therapeutics Inc [VERA] rating to a Buy in a research note published on October 16, 2025; the price target was $48. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who decreased its forecast for the stock in early August from “an Outperform” to “a Peer perform”. Wolfe Research started covering the stock on February 04, 2025. It rated VERA as “an Outperform”.
Price Performance Review of VERA
On Friday, Vera Therapeutics Inc [NASDAQ:VERA] saw its stock jump 1.26% to $33.75. Over the last five days, the stock has gained 21.10%. Vera Therapeutics Inc shares have fallen nearly -28.60% since the year began. Nevertheless, the stocks have fallen -20.19% over the past one year. While a 52-week high of $51.27 was reached on 01/06/25, a 52-week low of $18.53 was recorded on 04/09/25.
Levels Of Support And Resistance For VERA Stock
The 24-hour chart illustrates a support level at 33.29, which if violated will result in even more drops to 32.83. On the upside, there is a resistance level at 34.32. A further resistance level may holdings at 34.89.
How much short interest is there in Vera Therapeutics Inc?
A steep rise in short interest was recorded in Vera Therapeutics Inc stocks on 2025-11-14, growing by 0.21 million shares to a total of 9.96 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 9.76 million shares. There was a rise of 2.07%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 28, 2025 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $58 price target.
